What is Bimekizumab?

Bimekizumab is a humanized interleukin-17A and interleukin-17F antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults receiving systemic therapy or phototherapy. Plaque psoriasis is a chronic, immune-mediated inflammatory disease whose etiology is driven by pro-inflammatory cytokines.

Bimezumab works by selectively and directly inhibiting interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines that drive the inflammatory process in plaque psoriasis. It exerts its pharmacological effects by binding to and inhibiting a pro-inflammatory cytokine involved in the pathogenesis of psoriasis. Bimezumab is administered as a subcutaneous injection once monthly to patients by subcutaneous injection at weeks 0, 4, 8, 12 and 16 and then every 8 weeks thereafter. Complete all age-appropriate vaccinations before using bimezumab. Live vaccines should be avoided in patients receiving bimeclizumab.

Common adverse reactions to bimeclizumab include upper respiratory tract infection, oral candidiasis, headache, injection site reaction, ringworm infection, gastroenteritis, herpes simplex infection, acne, folliculitis, other candida infections, and fatigue.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.